Bq/cm3/MBq | SUV | Ratio | |||||
---|---|---|---|---|---|---|---|
Patient no. | Cell type | Tumor | Nontumor | Tumor | Nontumor | T/NT | SP/NSP |
11C-MeNTI | |||||||
1 | Squamous | 82.7* | 22.70 | 9.55 | 2.62 | 3.65 | 2.64 |
2 | Squamous | 98.3 | 29.35 | 8.85 | 2.64 | 3.35 | 2.35 |
3 | Adenocarcinoma | 70.6 | 10.55 | 4.65 | 0.70 | 6.69 | 5.69 |
4 | Adenocarcinoma | 99.4 | 32.25 | 6.78 | 2.20 | 3.08 | 2.08 |
6 | SCLC | 140.2 | 14.25 | 7.26 | 0.74 | 9.84 | 8.84 |
7 | SCLC | No uptake due to extensive necrosis | |||||
11C-CFN | |||||||
1 | Squamous | 40.4 | 13.54 | 4.66 | 1.56 | 2.99 | 1.98 |
2 | Squamous | 39.2 | 15.50 | 3.53 | 1.40 | 2.53 | 1.53 |
3 | Adenocarcinoma | 4.8 | 5.66 | 0.32 | 0.37 | 0.85 | −0.15 |
5 | Adenocarcinoma | 35.1 | 12.10 | 2.79 | 0.96 | 2.91 | 1.90 |
6 | SCLC | 42 | 5.35 | 2.18 | 0.28 | 7.85 | 6.85 |
7 | SCLC | No uptake due to extensive necrosis | |||||
18F-FDG | |||||||
1 | Squamous | 41.93 | 4.13 | 4.84 | 0.48 | 10.15 | 9.15 |
2 | Squamous | 52.33 | 6.17 | 4.71 | 0.56 | 8.49 | 7.49 |
4 | Adenocarcinoma | 57.60 | 7.67 | 3.80 | 0.51 | 7.51 | 6.51 |
5 | Adenocarcinoma | 120.08 | 13.65 | 9.55 | 1.09 | 8.80 | 7.80 |
↵* Mean activity over 60–90 min.
T/NT = tumor/nontumor ratio; SP = specific activity (tumor − nontumor); NSP = nonspecific activity (mean of 5 ROIs, 2 ipsilateral and 3 contralateral to tumor).